Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceutica (NQ: ENTA )

11.51 -0.32 (-2.75%)
Streaming Delayed Price Updated: 12:34 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Enanta Pharmaceutica

< Previous 1 2 3 4 Next >
10 Companies That Had Tons of Money in SVB When It Collapsed
Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB. 
Via InvestorPlace
Enanta Pharmaceuticals's Earnings: A Preview
Via Benzinga
Earnings Scheduled For November 21, 2022
Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earnings at $0.54 per share on revenue of $186.58 million. 
Via Benzinga
Earnings Outlook For Enanta Pharmaceuticals
Via Benzinga
Recap: Enanta Pharmaceuticals Q3 Earnings
  Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Ratings for Enanta Pharmaceuticals
Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Enanta Pharmaceuticals
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Where Enanta Pharmaceuticals Stands With Analysts
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study
Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple... 
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects.  EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a... 
Via Benzinga
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022
Upgrades 
Via Benzinga
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
Via Benzinga
Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid
Another company says it invented the technology behind the pill first. 
Via Investor's Business Daily
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading. 
Via Benzinga
Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has dosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL protease inhibitor, specifically designed as a... 
Via Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
Enanta Pharmaceuticals: Q1 Earnings Insights
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q1 earnings results on Tuesday, February 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals
Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Thursday
RBC Capital boosted KB Home (NYSE: KBH) price target from $46 to $55. KB Home shares rose 6.7% to $45.20 in pre-market trading. Cowen & Co. reduced the price target on... 
Via Benzinga
7 A-Rated Biotechs to Buy for the Long Run
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples. 
Via InvestorPlace
Where Enanta Pharmaceuticals Stands With Analysts
Over the past 3 months, 11 analysts have published their opinion on Enanta Pharmaceuticals (NASDAQ: 
Via Benzinga
Earnings Scheduled For February 8, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.